Biotech Values

[mcbio]

First thoughts on MNTA-BAX FoB partnership:

I’m fine with the financial terms—to the extent that they’ve been sketchily disclosed—but I don’t like BAX as the partner. BAX strikes me as firm that makes more than its share of mistakes for a medium-sized biotech and is habitually preoccupied with fighting regulatory fires such as manufacturing deficiencies and product recalls.

Maybe MNTA’s know-how will ensure BAX’s success in this endeavor, but I would have much preferred a partner such as PFE or SNY.

I’ll have more to say after the CC tomorrow.

Appreciate the fair take. Will be interesting to hear Wheeler go into more detail as to why BAX was the right fit. Regarding the financial terms and the royalties on the FoBs, I now see that MNTA disclosed that max royalty is "slightly more" than double the base rate so hopefully that gets us to about 20% max royalty if all criteria is met.

I am curious what those two initial FoBs are likely to be.